Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional Study Comparing Outcome of Patients Aged From 50 to 70 Years With or Without Donor
Authors not listed
Saint-Louis Hospital, Paris, France · 2008
Abstract
The purpose of this study is to compare outcome of high risk myelodysplasia patients aged from 50 to 70 years with or without HLA compatible (9 or 10 identities / 10) donor. High risk myelodysplasia includes IPSS intermediate 2 and high myelodysplasia and patients with sever thrombocytopenia. Patients are registered when they acquire risk factors.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-25 MST
Cite this
APA
Anonymous. (2008). Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional Study Comparing Outcome of Patients Aged From 50 to 70 Years With or Without Donor. <em>Saint-Louis Hospital, Paris, France</em>. https://clinicaltrials.gov/study/NCT01095874
Vancouver
Anonymous. Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional Study Comparing Outcome of Patients Aged From 50 to 70 Years With or Without Donor. Saint-Louis Hospital, Paris, France. 2008.
BibTeX
@misc{anon2008Alloge,
title = {Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional Study Comparing Outcome of Patients Aged From 50 to 70 Years With or Without Donor},
author = {Anonymous},
journal = {Saint-Louis Hospital, Paris, France},
year = {2008},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Peking University People's Hospital 2018
Open access · US-GOV
Reduced Intensity Conditioning Regimen for Elderly or High Comorbidity Burden Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation
Lymphoma Study Association 2003
Open access · US-GOV
Study of ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 59 Years With High Risk Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 2-3)
Respirology 2026
Open access · OA
Frailty, Chronological Age, and Clinical Outcomes in COPD : A Nationwide Cohort Study
Lymphoma Study Association 1999
Open access · US-GOV
Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma
Charite University, Berlin, Germany 2016
Open access · US-GOV
Frailty and Post-operative Complications in Older Surgical Patients: The Implication of Frailty and Preoperative Risk Assessment - A Retrospective Analysis
The First Affiliated Hospital of Soochow University 2021
Open access · US-GOV